Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clobetasol Propionate 0.05% Shampoo in Association With Antifungal Shampoo in Scalp Seborrheic Dermatitis (Escape)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Galderma
ClinicalTrials.gov Identifier:
NCT00862654
First received: March 15, 2009
Last updated: August 31, 2011
Last verified: August 2011
  Purpose

The objective is to assess different treatment regimens with Clobetasol propionate shampoo 0.05% in the treatment of scalp Seborrheic Dermatitis.


Condition Intervention Phase
Scalp Seborrheic Dermatitis
Drug: clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)
Drug: clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)
Drug: clobetasol propionate shampoo (2/week)
Drug: ketoconazole shampoo (2/week)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Clobetasol Propionate Shampoo 0.05% Used in Association With an Antifungal Shampoo in the Treatment of Moderate to Severe Scalp Seborrheic Dermatitis

Resource links provided by NLM:


Further study details as provided by Galderma:

Primary Outcome Measures:
  • Total Severity Score (TSS): Percent Change From Baseline at Week 4 [ Time Frame: baseline and week 4 ] [ Designated as safety issue: No ]
    Total Severity Score (TSS) is sum of erythema, scaling and pruritus severity scores of the lesions evaluated each on a 4-point scale from 0 = None to 3 = Severe by the investigator. So minimum TSS can be 0 and maximum 9.


Enrollment: 326
Study Start Date: March 2009
Study Completion Date: February 2010
Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: C propionate 4/week + Ketoconasole 2/week
Clobetasol propionate shampoo 0.05% (4/week) + Ketoconazole shampoo 2% (2/week)
Drug: clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)
Association: clobetasol propionate shampoo & ketoconazole shampoo
Experimental: C propionate 2/week + Ketoconasole 2/week
Clobetasol propionate shampoo 0.05% (2/week) + Ketoconazole shampoo 2% (2/week)
Drug: clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)
Association: clobetasol propionate shampoo & ketoconazole shampoo
Experimental: C propionate 2/week
Clobetasol propionate shampoo 0.05% (2/week)
Drug: clobetasol propionate shampoo (2/week)
Monotherapy with clobetasol propionate shampoo
Active Comparator: Ketoconazole 2/week
Ketoconazole shampoo 2% (2/week)
Drug: ketoconazole shampoo (2/week)
Monotherpay ketoconazole shampoo (2/week)

Detailed Description:

The objective is to assess different treatment regimens with Clobetasol propionate shampoo 0.05% in association with an antifungal shampoo (Ketoconazole 2%) in the treatment of moderate to severe scalp Seborrheic Dermatitis compared to the antifungal shampoo alone.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with moderate to severe scalp Seborrheic Dermatitis

Exclusion Criteria:

  • Subjects suffering from psoriasis,
  • Subjects with a known allergy to one of the components of the test products,
  • Female subjects who are pregnant, nursing or planning a pregnancy during the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00862654

Locations
Belgium
Galderma Investigational Center
Brugge, Belgium
Galderma Investigational Center
Bruxelles, Belgium
Galderma Investigational Center
Geel, Belgium
Galderma Investigational Center
Gent, Belgium
Galderma Investigational Center
Liege, Belgium
Galderma Investigational Center
Mons, Belgium
France
Galderma Investigational Center
Paris, France
Germany
Galderma Investigational Center
Berlin, Germany
Galderma Investigational Center
Bonn, Germany
Galderma Investigational Center
Hamburg, Germany
Galderma Investigational Center
Lubeck, Germany
Galderma Investigational Center
Mahlow, Germany
Galderma Investigational Center
Wuppertal, Germany
Korea, Republic of
Galderma Investigational Center
Seoul, Korea, Republic of
Mexico
Galderma Investigational Center
Guadalajara, Mexico
Galderma Investigational Center
Mexico, Mexico
Galderma Investigational Center
Naucalpan, Mexico
Galderma Investigational Center
Zapopan, Jalisco, Mexico
Sponsors and Collaborators
Galderma
Investigators
Principal Investigator: Jean-Paul Ortonne, MD Nice Hospital (France)
  More Information

Additional Information:
No publications provided by Galderma

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Galderma
ClinicalTrials.gov Identifier: NCT00862654     History of Changes
Other Study ID Numbers: RD.03.SPR.29079
Study First Received: March 15, 2009
Results First Received: June 15, 2011
Last Updated: August 31, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Belgium: Federal Agency for Medicinal Products and Health Products
Mexico: Ministry of Health
South Korea: Korea Food and Drug Administration (KFDA)

Additional relevant MeSH terms:
Dermatitis
Dermatitis, Seborrheic
Sebaceous Gland Diseases
Skin Diseases
Skin Diseases, Eczematous
Skin Diseases, Papulosquamous
Clobetasol
Ketoconazole
14-alpha Demethylase Inhibitors
Anti-Infective Agents
Anti-Inflammatory Agents
Antifungal Agents
Enzyme Inhibitors
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014